Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma.
Ontology highlight
ABSTRACT: Asthmatic airways are inflamed and undergo remodelling. Inhaled corticosteroids and long-acting ?2-agonist combinations are more effective than inhaled corticosteroid monotherapy in controlling disease exacerbations, but their effect on airway remodelling and inflammation remains ill-defined. This study evaluates the contribution of inhaled fluticasone and salmeterol, alone or combined, to the reversal of bronchial remodelling and inflammation. Severely asthmatic horses (6 horses/group) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance for 12 weeks. Lung function, central and peripheral airway remodelling, and bronchoalveolar inflammation were assessed. Fluticasone/salmeterol and fluticasone monotherapy decreased peripheral airway smooth muscle remodelling after 12 weeks (p?=?0.007 and p?=?0.02, respectively). On average, a 30% decrease was observed with both treatments. In central airways, fluticasone/salmeterol reversed extracellular matrix remodelling after 12 weeks, both within the lamina propria (decreased thickness, p?=?0.005) and within the smooth muscle layer (p?=?0.004). Only fluticasone/salmeterol decreased bronchoalveolar neutrophilia (p?=?0.03) to the same extent as antigen avoidance already after 8 weeks. In conclusion, this study shows that fluticasone/salmeterol combination decreases extracellular matrix remodelling in central airways and intraluminal neutrophilia. Fluticasone/salmeterol and fluticasone monotherapy equally reverse peripheral airway smooth muscle remodelling.
SUBMITTER: Bullone M
PROVIDER: S-EPMC5562887 | biostudies-other | 2017 Aug
REPOSITORIES: biostudies-other
ACCESS DATA